Motilal Oswal has maintained a 'Buy' rating on Ajanta Pharma with a target price of Rs 3,145, citing potential for significant upside. The brokerage highlights the company's strategic shift towards a chronic-focused portfolio, expansion into new geographies, and enhancement of product offerings. Ajanta Pharma's strong medical representative presence and focus on emerging markets are expected to drive outperformance against the industry.